WHO Drug Information, Vol. 22, No. 1, 2008                                                 Recommended INN: List 59



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 59
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List
No. 12, 2007 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 59
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies
par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la
substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans
la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 59
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran
reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM).




                                                                                                                    41
Recommended INN: List 59                                                        WHO Drug Information, Vol. 22, No. 1, 2008




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 alaninati brivanibum
 brivanib alaninate                        (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo=
                                           [2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-yl L-alaninate

 alaninate de brivanib                     L-alaninate de (2R)-1-({4-[(4-fluoro-2-méthyl-1H-indol-5-yl)oxy]-
                                           5-méthylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-yle

 alaninato de brivanib                     L-alaninato de (2R)-1-({4-[(4-fluoro-2-metil-1H-indol-5-il)oxi]-
                                           5-metilpirrolo[2,1-f][1,2,4]triazin-6-il}oxi)propan-2-ilo

                                           C22H24FN5O4

                                                                                       N
                                                                                   N         N
                                                 H    CH3
                                                            O
                                            H2N                          O                   O                  NH
                                                        O     H    CH3             CH3
                                                                                                  F                  CH3


 albiglutidum*
 albiglutide                               ([8-glycine]human glucagon-like peptide 1-(7-36)-peptidyl)
                                           ([8-glycine]human glucagon-like peptide 1-(7-36)-peptidyl)(human
                                           serum albumin (585 residues))

 albiglutide                               ([8-glycine]peptide 1 analogue au glucagon humain-(7-36)-
                                           peptidyl)([8-glycine]peptide 1 analogue au glucagon humain-
                                           (7-36)-peptidyl)(albumine sérique humaine (585 aminoacides))

 albiglutida                               ([8-glicina]péptido1 análogo al glucagón humano-(7-36)-peptidil)
                                           ([8-glicina]péptido 1 análogo al glucagón humano-(7-36)-
                                           peptidil)(albumina séria humana (585 aminoácidos))

                                           C3232H5032N864O979S41

                                            HGEGTFTSDV          SSYLEGQAAK        EFIAWLVKGR          HGEGTFTSDV        SSYLEGQAAK          50
                                            EFIAWLVKGR          DAHKSEVAHR        FKDLGEENFK          ALVLIAFAQY        LQQCPFEDHV          100
                                            KLVNEVTEFA          KTCVADESAE        NCDKSLHTLF          GDKLCTVATL        RETYGEMADC          150
                                            CAKQEPERNE          CFLQHKDDNP        NLPRLVRPEV          DVMCTAFHDN        EETFLKKYLY          200
                                            EIARRHPYFY          APELLFFAKR        YKAAFTECCQ          AADKAACLLP        KLDELRDEGK          250
                                            ASSAKQRLKC          ASLQKFGERA        FKAWAVARLS          QRFPKAEFAE        VSKLVTDLTK          300
                                            VHTECCHGDL          LECADDRADL        AKYICENQDS          ISSKLKECCE        KPLLEKSHCI          350
                                            AEVENDEMPA          DLPSLAADFV        ESKDVCKNYA          EAKDVFLGMF        LYEYARRHPD          400
                                            YSVVLLLRLA          KTYETTLEKC        CAAADPHECY          AKVFDEFKPL        VEEPQNLIKQ          450
                                            NCELFEQLGE          YKFQNALLVR        YTKKVPQVST          PTLVEVSRNL        GKVGSKCCKH          500
                                            PEAKRMPCAE          DYLSVVLNQL        CVLHEKTPVS          DRVTKCCTES        LVNRRPCFSA          550
                                            LEVDETYVPK          EFNAETFTFH        ADICTLSEKE          RQIKKQTALV        ELVKHKPKAT          600
                                            KEQLKAVMDD          FAAFVEKCCK        ADDKETCFAE          EGKKLVAASQ        AALGL               645

                                            Disulfide bridges location Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            113-122 135-151 150-161 184-229 228-237 260-306 305-313 325-339 338-349
                                            376-421 420-429 452-498 497-508 521-537 536-547 574-619 618-627




42
WHO Drug Information, Vol. 22, No. 1, 2008                                                                Recommended INN: List 59


 albinterferonum alfa-2b*
 albinterferon alfa-2b                       human serum albumin (585 residues) fusion protein with human
                                             interferon α-2b (165 residues)

 albinterféron alfa-2b                       protéine de fusion entre l’albumine sérique humaine (585
                                             aminoacides) et l'interféron α-2b humain (165 aminoacides)

 albinterferón alfa 2b                       proteína de fusión entre la albumina sérica humana (585
                                             aminoácidos) y el interferón α-2b humano (165 aminoácidos)

                                             C3796H5937N1015O1143S50

                                             DAHKSEVAHR          FKDLGEENFK        ALVLIAFAQY          LQQCPFEDHV         KLVNEVTEFA           50
                                             KTCVADESAE          NCDKSLHTLF        GDKLCTVATL          RETYGEMADC         CAKQEPERNE           100
                                             CFLQHKDDNP          NLPRLVRPEV        DVMCTAFHDN          EETFLKKYLY         EIARRHPYFY           150
                                             APELLFFAKR          YKAAFTECCQ        AADKAACLLP          KLDELRDEGK         ASSAKQRLKC           200
                                             ASLQKFGERA          FKAWAVARLS        QRFPKAEFAE          VSKLVTDLTK         VHTECCHGDL           250
                                             LECADDRADL          AKYICENQDS        ISSKLKECCE          KPLLEKSHCI         AEVENDEMPA           300
                                             DLPSLAADFV          ESKDVCKNYA        EAKDVFLGMF          LYEYARRHPD         YSVVLLLRLA           350
                                             KTYETTLEKC          CAAADPHECY        AKVFDEFKPL          VEEPQNLIKQ         NCELFEQLGE           400
                                             YKFQNALLVR          YTKKVPQVST        PTLVEVSRNL          GKVGSKCCKH         PEAKRMPCAE           450
                                             DYLSVVLNQL          CVLHEKTPVS        DRVTKCCTES          LVNRRPCFSA         LEVDETYVPK           500
                                             EFNAETFTFH          ADICTLSEKE        RQIKKQTALV          ELVKHKPKAT         KEQLKAVMDD           550
                                             FAAFVEKCCK          ADDKETCFAE        EGKKLVAASQ          AALGLCDLPQ         THSLGSRRTL           600
                                             MLLAQMRRIS          LFSCLKDRHD        FGFPQEEFGN          QFQKAETIPV         LHEMIQQIFN           650
                                             LFSTKDSSAA          WDETLLDKFY        TELYQQLNDL          EACVIQGVGV         TETPLMKEDS           700
                                             ILAVRKYFQR          ITLYLKEKKY        SPCAWEVVRA          EIMRSFSLST         NLQESLRSKE           750

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

                                             53-62   75-91   90-101 124-169 168-177 200-246 245-253 265-279
                                             278-289 316-361 360-369 392-438 437-448 461-477 476-487 514-559
                                             558-567 586-683 614-723

                                             Glycosylation sites : N-318 T-691


 anamorelinum
 anamorelin                                  (3R)-3-benzyl-N,N',N'-trimethyl-1-{2-methylalanyl-D-tryptophyl}=
                                             piperidine-3-carbohydrazide

 anamoréline                                 (3R)-3-benzyl-N,N',N'-triméthyl-1-(2-méthylalanyl-D-tryptophyl)=
                                             pipéridine-3-carbohydrazide

 anamorelina                                 (3R)-3-bencil-N,N',N'-trimetil-1-{2-metilalanil-D-triptofil}piperidina-
                                             3-carbohidrazida

                                             C31H42N6O3

                                              H3C      CH3           O                 O        CH3
                                                             H
                                                             N                                  N
                                             H2N                          N                N        CH3
                                                        O      H                           CH3


                                                         HN




 apremilastum
 apremilast                                  N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methanesulfonyl)ethyl]-
                                             1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

 aprémilast                                  N-{2-[(1S)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthanesulfonyl)éthyl]-
                                             1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acétamide

 apremilast                                  N-{2-[(1S)-1-(3-etoxi-4-metoxifenil)-2-(metansulfonil)etil]-1,3-dioxo-
                                             2,3-dihidro-1H-isoindol-4-il}acetamida


                                                                                                                                                 43
Recommended INN: List 59                                      WHO Drug Information, Vol. 22, No. 1, 2008


                            C22H24N2O7S

                                                      O O
                                              O        S
                                                         CH3
                                                       H
                                              N
                                                                            CH3
                            H 3C       NH     O                       O


                                   O                              OCH3


 arbaclofenum placarbilum
 arbaclofen placarbil       (3R)-3-(4-chlorophenyl)-4-[({(1S)-2-methyl-1-[(2-methylpropanoyl)=
                            oxy]propoxy}carbonyl)amino]butanoic acid

 arbaclofène placarbil      acide (3R)-3-(4-chlorophényl)-4-[({(1S)-2-méthyl-
                            1-[(2-méthylpropanoyl)oxy]propoxy}carbonyl)amino]butanoïque

 arbaclofeno placarbilo     ácido (3R)-3-(4-clorofenil)-4-[({(1S)-2-metil-1-[(2-metilpropanoil)=
                            oxi]propoxi}carbonil)amino]butanoico

                            C19H26ClNO6

                                       H 3C       CH3
                                       O            O
                                                  H
                            H3C
                                         O        O       N                 CO2H
                                                          H
                                   CH3                            H



                                                                            Cl


 arterolanum
 arterolane                 N-(2-amino-2-methylpropyl)-2-{cis-dispiro[adamantane-
                            2,3'-[1,2,4]trioxolane-5',1"-cyclohexan]-4"-yl}acetamide

 artérolane                 N-(2-amino-2-methylpropyl)-2-{cis-dispiro[adamantane-
                            2,3'-[1,2,4]trioxolane-5',1"-cyclohexan]-4"-yl}acétamide

 arterolano                 N-(2-amino-2-metilpropil)-2-{cis-dispiro[adamantano-
                            2,3'-[1,2,4]trioxolano-5',1"-ciclohexan]-4"-il}acetamida

                            C22H36N2O4

                                         O                    O
                                   O                  H
                                                                             CH3
                                                                  N
                                         O                        H
                                                                      H2N   CH3



 azilsartanum medoxomilum
 azilsartan medoxomil       (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-
                            4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl}-
                            1H-benzimidazol-7-carboxylate

 azilsartan médoxomil       2-éthoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-
                            1,1'-biphényl-4-yl]méthyl}-1H-benzimidazole-7-carboxylate de
                            (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle




44
WHO Drug Information, Vol. 22, No. 1, 2008                                                                  Recommended INN: List 59


 azilsartán medoxomilo                       2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)-1,1'-bifenil-
                                             4-il]metil}-1H-benzoimidazol-7-carboxilato de (5-metil-2-oxo-
                                             1,3-dioxol-4-il)metilo

                                             C30H24N4O8

                                                      O

                                                  O         O


                                             H3C                 O
                                                                                           O
                                                                             O
                                                                                                    O
                                                                                           HN           N
                                                                             N

                                                                     N           O

                                                                                     CH3



 azoximeri bromidum
 azoximer bromide                            poly{[1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide]ethylene-
                                             co-[(piperazin-1,4-diyl 1-oxide)ethylene]}

 bromure d'azixomère                         poly{[bromure de 1-(carboxyméthyl)pipérazin-1-ium-
                                             1,4-diyl]éthylène-co-[(1-oxyde de pipérazine-1,4-diyl)éthylène]}

 bromuro de azoxímero                        poly{[bromuro de 1-(carboximetil)piperazin-1-io-1,4-diil]etileno-
                                             co-[(1-óxido de piperazin-1,4-diil)etileno]}

                                             [[C8H15BrN2O2]x[C6H12N2O]y]n


                                                          CO2H

                                                          N+
                                                                 N
                                                   Br
                                                                         x             N   N
                                                                                 O              y
                                                                                                    n




 begacestatum
 begacestat                                  5-chloro-N-[(2S)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-
                                             2-yl]thiophene-2-sulfonamide

 bégacestat                                  5-chloro-N-[(2S)-4,4,4-trifluoro-1-hydroxy-3-(trifluorométhyl)butan-
                                             2-yl]thiophène-2-sulfonamide

 begacestat                                  5-cloro-N-[(2S)-4,4,4-trifluoro-1-hidroxi-3-(trifluorometil)butan-
                                             2-il]tiofeno-2-sulfonamida

                                             C9H8ClF6NO3S2

                                                                O O H                OH
                                                        S        S                   CF3
                                             Cl                      N
                                                                     H
                                                                                 CF3




                                                                                                                                  45
Recommended INN: List 59                              WHO Drug Information, Vol. 22, No. 1, 2008


 belataceptum
                              29    104     125     130    136       139   148
 belatacept                [Tyr ,Glu ,Gln ,Ser ,Ser ,Ser ,Ser ](antigen CTLA-4
                           human-3-126]-peptide (fragment containing the human extracellular
                           domain) fusion protein with immunoglobulin G1-[233 amino acids
                           from the C-terminal of the heavy chain]-peptide (fragment containing
                           the human monoclonal Fc domain), bimolecular (120→120')-disulfide

 bélatacept                (120→120')-disulfure bimoléculaire de
                               29    104     125   130    136   139     148
                           [Tyr ,Glu ,Gln ,Ser ,Ser ,Ser ,Ser ](antigène CTLA-4
                           humain-[3-126]-peptide (fragment contenant le domaine
                           extracellulaire) protéine de fusion avec l’immunoglobuline G1-[233
                           aminoacides C-terminaux de la chaîne lourde]-peptide (fragment
                           contenant le domaine Fc de l’anticorps monoclonal humain))

 belatacept                (120→120')-disulfuro bimolecular de
                               29    104    125    130   136   139    148
                           [Tyr ,Glu ,Gln ,Ser ,Ser ,Ser ,Ser ](antígeno CTLA-4
                           humano-[3-126]-péptido (fragmento que contiene el dominio
                           extracelular) proteína de fusión con la inmunoglobulina G1-[233
                           aminoácidos C-terminales de la cadena pesada]-péptido (fragmento
                           que contiene el dominio Fc del anticuerpo monoclonal humano))

                           C3508H5440N922O1096S32

                            MHVAQPAVVL        ASSRGIASFV
                            CEYASPGKYT EVRVTVLRQA
                            DSQVTEVCAA        TYMMGNELTF
                                            *
                            LDDSICTGTS SGNQVNLTIQ
                            GLRAMDTGLY ICKVELMYPP
                                   *
                            PYYEGIGNGT        QIYVIDPEPC
                                    *
                            PDSDQEPKSS               *
                                             DKTHTSPPSP
                            APELLGGSSV FLFPPKPKDT
                            LMISRTPEVT CVVVDVSHED
                            PEVKFNWYVD        GVEVHNAKTK
                                  *
                            PREEQYNSTY        RVVSVLTVLH
                            QDWLNGKEYK CKVSNKALPA
                            PIEKTISKAK        GQPREPQVYT
                            LPPSRDELTK        NQVSLTCLVK
                            GFYPSDIAVE        WESNGQPENN
                            YKTTPPVLDS DGSFFLYSKL
                            TVDKSRWQQG        NVFSCSVMHE
                             ALHNHYTQKS LSLSPGK
                                                                 2

                               * glycosylation sites
                               * sites de glycosylation
                               * posiciónes de glicosilación



 belinostatum
 belinostat                N-hydroxy-3-[3-(N-phenylsulfamoyl)phenyl]prop-2-enamide

 bélinostat                N-hydroxy-3-[3-(phénylsulfamoyl)phényl]prop-2-ènamide

 belinostat                N-hidroxi-3-{3-[(fenilsulfamoil]fenil}prop-2-enamida




46
WHO Drug Information, Vol. 22, No. 1, 2008                                                      Recommended INN: List 59


                                             C15H14N2O4S

                                                                               O
                                                      H                                OH
                                                      N                            N
                                                          S                        H
                                                       O O




 boceprevirum
 boceprevir                                  (1R,2S,5S)-N-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]-
                                             3-{(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl}-
                                             6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

 bocéprévir                                  (1R,2S,5S)-N-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]-
                                             3-{(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-diméthylbutanoyl}-
                                             6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

 boceprevir                                  (1R,2S,5S)-N-[(2Ξ)-4-amino-1-ciclobutil-3,4-dioxobutan-2-il)]-
                                             3-{(2S)-2-[(terc-butilcarbamoil)amino]-3,3-dimetilbutanoil}-6,6-dimetil-
                                             3-azabiciclo[3.1.0]hexano-2-carboxamida

                                             C27H45N5O5

                                                                  CH3              CH3
                                                          H3C          H
                                                                   CH3              CH3
                                              H3C   CH3 O                                   O
                                                                   H
                                                                       N        H
                                             H3C      N       N                HN                   NH2
                                                      H       H
                                                                   O       H
                                                                               O       H        O




 canakinumabum*
 canakinumab                                 immunoglobulin G1, anti-[Homo sapiens interleukin 1, beta (IL1B)]
                                             human monoclonal ACZ885; gamma1 heavy chain (Homo sapiens
                                             VH-IGHG1*03) (221-214’)-disulfide with kappa light chain (Homo
                                             sapiens V-KAPPA-IGKC*01); (227-227’’:230-230’’)-bisdisulfide dimer

 canakinumab                                 immunoglobuline G1, anti-[Homo sapiens interleukine 1, beta (IL1B)]
                                             anticorps monoclonal humain ACZ885; chaîne lourde gamma1
                                             (Homo sapiens VH-IGHG1*03) (221-214’)-disulfure avec la chaîne
                                             légère kappa (Homo sapiens V-KAPPA-IGKC*01); dimère (227-
                                             227’’:230-230’’)-bisdisulfure

 canakinumab                                 inmunoglobulina G1, anticuerpo monoclonal humano ACZ885
                                             anti-[ interleukina 1 de Homo sapiens, beta (IL1B)]; cadena pesada
                                             gamma1 (Homo sapiens VH-IGHG1*03) (221-214’)-disulfuro con la
                                             cadena ligera kappa (Homo sapiens V-KAPPA-IGKC*01); dímero
                                             (227-227’’:230-230’’)-bisdisulfuro

                                             C6452H9958N1722O2010S42




                                                                                                                      47
Recommended INN: List 59                                           WHO Drug Information, Vol. 22, No. 1, 2008


 carfilzomibum
 carfilzomib               {(2S)-2-[(morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-
                             1
                           N -{(2S)-1-[(2R)-2-methyloxiran-2-yl]-4-methyl-1-oxopentan-2-yl}-
                           L-phenylalaninamide

 carfilzomib               {(2S)-2-[(morpholin-4-yl)acétamido]-4-phénylbutanoyl}-L-leucyl-
                             1
                           N -{(2S)-1-[(2R)-2-méthyloxiran-2-yl]-4-méthyl-1-oxopentan-2-yl}
                           -L-phénylalaninamide

 carfilzomib               {(2S)-2-[(morfolin-4-il)acetamido]-4-fenilbutanoil}-L-leucil-
                             1
                           N -{(2S)-1-[(2R)-2-metiloxiran-2-il]-4-metil-1-oxopentan-2-il}-
                           L-fenilalaninamida

                           C40H57N5O7




                           O                   O       H               O          H            O
                                                               H                       H
                                   N                           N                       N              CH3
                                                   N                         N
                                                   H                         H
                                                           O           H          O            H O
                                                                           CH3                  CH3
                                                               H3C                    H3 C



 ceftarolinum fosamilum
 ceftaroline fosamil       (6R,7R)-7-{(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-
                           1,2,4-thiadiazol-3-yl]acetamido}-3-{[4-(1-methylpyridin-1-ium-4-yl)-
                           1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
                           2-carboxylate

 céftaroline fosamil       (6R,7R)-7-{(2Z)-2-(éthoxyimino)-2-[5-(phosphonoamino)-
                           1,2,4-thiadiazol-3-yl]acétamido}-3-{[4-(1-méthylpyridin-1-ium-4-yl)-
                           1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-
                           2-carboxylate

 ceftarolina fosamilo      (6R,7R)-7-{(2Z)-2-(etoxiimino)-2-[5-(fosfonoamino)-1,2,4-tiadiazol-
                           3-il]acetamido}-3-{[4-(1-metilpiridin-1-io-4-il)-1,3-tiazol-2-il]sulfanil}-
                           8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxilato

                           C22H21N8O8PS4

                                                           CH3
                                                                            CO2
                                                       O       O                  S        N
                                                   N                   N
                                                           H                                            N+ CH3
                                           N               N                          S
                                                                            S
                                       S                           H   H
                             HO                N       O
                           HO          NH
                              P
                               O




48
WHO Drug Information, Vol. 22, No. 1, 2008                                                   Recommended INN: List 59


 cenersenum
 cenersen                                    antisense oligonucleotide inhibitor of p53 expression
                                             2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-
                                             deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-
                                             thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                                             (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                             (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                             (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                             (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                                             deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-
                                             deoxycytidine

 cénersen                                    oligonucléotide antisense inhibiteur de l'expression de p53
                                             2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-
                                             déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-
                                             thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-
                                             (3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                             (3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                             (3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                             (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                             déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-
                                             thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-
                                             déoxycytidine

 cenersén                                    oligonucleótido antisentido inhibidor de la expresión de p53
                                             2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                                             P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-
                                             (3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-
                                             tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-
                                             (3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-
                                             desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-
                                             (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                                             P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxicitidina


                                             C187H226N62O103P19S19



 cholini fenofibratum
 choline fenofibrate                         2-hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)=
                                             phenoxy]-2-methylpropanoate

 fénofibrate de choline                      2-[4-(4-chlorobenzoyl)phénoxy]-2-méthylpropanoate de 2-hydroxy-
                                             N,N,N-triméthyléthanaminium

 fenofibrato de colina                       2-[4-(4-clorobenzoil)fenoxi]-2-metilpropanoato de 2-hidroxi-
                                             N,N,N-trimetiletanaminio
                                                       +              -
                                             C5H14NO .C17H14ClO4

                                                                          Cl                       O     CO2-
                                                     H3C
                                                                CH3
                                                           N+                                     H3 C   CH3
                                             HO                 CH3
                                                                                     O




                                                                                                                           49
Recommended INN: List 59                                WHO Drug Information, Vol. 22, No. 1, 2008


 cinaciguatum
 cinaciguat                  4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)phenyl]methoxy}=
                             phenyl)ethyl]amino}methyl)benzoic acid

 cinaciguat                  acide 4-({(4-carboxybutyl)[2-(2-{[4-(2-phényléthyl)phényl]méthoxy}=
                             phényl)éthyl]amino}méthyl)benzoïque

 cinaciguat                  ácido 4-({(4-carboxibutil)[2-(2-{[4-(2-feniletil)fenil]metoxi}fenil)=
                             etil]amino}metil)benzoico

                             C36H39NO5

                                                                                    CO2H


                                                          O
                                                                       N
                                                                                       CO2H




 contusugenum ladenovecum*
 contusugene ladenovec       (Recombinant) replication restricted adenovirus (type 5) vector, E1
                             deleted, partial E3 deletion, containing/expressing a wild type p53
                             gene driven by a cytomegalovirus promoter

 contusugène ladénovec       Vecteur adénovirus (type 5) recombinant défectif, délété de E1 et
                             partiellement de E3, contenant le gène p53 sauvage sous le contrôle
                             du promoteur cytomégalovirus

 contusugén ladenovec        Vector adenovirus (tipo 5) recombinante defectivo, con deleción de
                             E1 y parcialmente de E3, que contiene el gen p53 salvaje controlado
                             por el promotor de cytomegalovirus




 dapagliflozinum
 dapagliflozin               (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-
                             D-glucitol

 dapagliflozine              (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-éhoxyphényl)méthyl]phényl}-
                             D-glucitol

 dapagliflozina              (1S)-1,5-anhidro-1-C-{4-cloro-3-[(4-etoxifenil)metil]fenil}-D-glucitol

                             C21H25ClO6

                                    O       CH3




                                            Cl

                             HO

                                        O
                                  OH
                             HO
                                        OH




50
WHO Drug Information, Vol. 22, No. 1, 2008                                                          Recommended INN: List 59


 delimotecanum
 delimotecan                                 poly{[2-O-(carboxymethyl)-α-D-glucopyranosyl-(1→6)]-co-[2-O-(15-
                                             {[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-
                                             1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}-
                                             2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecyl)-α-D-glucopyranosyl-
                                             (1→6)]-co-[α-D-glucopyranosyl-(1→6)]}

 délimotécan                                 poly{[2-O-(carboxyméthyl)-α-D-glucopyranosyl-(1→6)]-co-[2-O-(15-
                                             {[(4S)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-
                                             1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-9-yl]oxy}-
                                             2,5,8,11-tétraoxo-3,6,9,12-tétraazapentadécyl)-α-D-glucopyranosyl-
                                             (1→6)]-co-[α-D-glucopyranosyl-(1→6)]}

 delimotecán                                 poli{[2-O-(carboximetil)-α-D-glucopiranosil-(1→6)]-co-[2-O-(15-{[(4S)-
                                             4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-
                                             1H-pirano[3',4':6,7]indolizino[1,2-b]quinolin-9-il]oxi}-
                                             2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecil)-α-D-glucopiranosil-
                                             (1→6)]-co-[α-D-glucopiranosil-(1→6)]}

                                             [C39H46N6O14[C6H10O5]x[C8H12O7]y]n

                                             HO
                                                                                   O
                                                                              OH
                                                                         HO            O
                                                                                   OH      x
                                                               O
                                                                    CH3
                                                          O
                                                                                                             O
                                                                    OH                                  OH
                                                    O                                              HO            O
                                                         N                                     HO2C          O
                                                                                                                     y
                                                                                                                              O
                                                                N
                                                                                                                         OH
                                                  H3C
                                                                                                                 HO               O
                                                                                                                                          H
                                                                                                                              O
                                                                                                   O
                                                                               H                         H
                                                               O               N                         N
                                                                                               N                     N        O
                                                                                               H                     H
                                                                                   O                         O                        n




 dovitinibum
 dovitinib                                   4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazole-
                                             2-yl]quinolin-2(1H)-one

 dovitinib                                   4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-
                                             2-yl]quinoléin-2(1H)-one

 dovitinib                                   4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1H-benzoimidazol-
                                             2-il]quinolin-2(1H)-ona




                                                                                                                                              51
Recommended INN: List 59                                      WHO Drug Information, Vol. 22, No. 1, 2008


                           C21H21FN6O


                                 O           N                N          N CH3

                            HN                   N
                                                 H
                                             NH2

                                         F


 eldecalcitolum
 eldecalcitol              (5Z,7E)-2β-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-
                           1α,3β,25-triol

 eldécalcitol              (5Z,7E)-2β-(3-hydroxypropoxy)-9,10-sécocholesta-5,7,10(19)-triène-
                           1α,3β,25-triol

 eldecalcitol              (5Z,7E)-2β-(3-hidroxipropoxi)-9,10-secocolesta-5,7,10(19)-trieno-
                           1α,3β,25-triol

                           C30H50O5

                                                     H3 C H
                                                     CH3                      CH3
                                                               H
                                                                              CH3
                                                                         HO

                                                     H


                                                     CH2

                                 HO                      OH
                                         H           H
                           HO                O H



 elvitegravirum
 elvitegravir              6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-
                           2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

 elvitégravir              acide 6-[(3-chloro-2-fluorophényl)méthyl]-1-[(2S)-1-hydroxy-
                           3-méthylbutan-2-yl]-7-méthoxy-4-oxo-1,4-dihydroquinoline-
                           3-carboxylique

 elvitegravir              ácido 6-[(3-cloro-2-fluorofenil)metil]-1-[(2S)-1-hidroxi-3-metilbutan-
                           2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico

                           C23H23ClFNO5

                                                                   CH3
                                                     HO
                                              CH3         H          CH3
                                              O               N


                           Cl                                        CO2H
                                     F                        O




52
WHO Drug Information, Vol. 22, No. 1, 2008                                                                 Recommended INN: List 59


 epetirimodum
 epetirimod                                  1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

 épétirimod                                  1-(2-méthylpropyl)-1H-imidazo[4,5-c][1,5]naphtyridin-4-amine

 epetirimod                                  1-(2-metilpropil)-1H-imidazo[4,5-c][1,5]naftiridin-4-amina

                                             C13H15N5

                                             H3C

                                             H3C        N
                                                N                 N


                                                        N         NH2


 epoetinum kappa
 epoetin kappa                               1-165-erythropoietin (human JR-013), glycoform κ

 époétine kappa                              érythropoïétine (humaine JR-013)-(1-165), glycoforme κ

 epoetina kappa                              1-165-eritropoyetina (humana JR-013), glicoforma κ

                                             C809H1301N229O240S5


 eribulinum
 eribulin                                    (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24
                                             S,26R,28R,29aS)-2-[(2S)-3-amino-2-hydroxypropyl]-3-methoxy-
                                             26-methyl-20,27-dimethylidenehexacosahydro-11,15:18,21:24,28-
                                             triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-
                                             i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one

 éribuline                                   (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24
                                             S,26R,28R,29aS)-2-[(2S)-3-amino-2-hydroxypropyl]-3-méthoxy-
                                             26-méthyl-20,27-diméthylidènehexacosahydro-11,15:18,21:24,28-
                                             triépoxy-7,9-éthano-12,15-méthano-9H,15H-furo[3,2-
                                             i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one

 eribulina                                   (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24
                                             S,26R,28R,29aS)-2-[(2S)-3-amino-2-hidroxipropil]-26-metil-
                                             20,27-dimetilideno-3-metoxihexacosahidro-11,15:18,21:24,28-
                                             triepoxi-7,9-etano-12,15-metano-9H,15H-furo[3,2-i]furo=
                                             [2',3':5,6]pirano[4,3-b][1,4]dioxaciclopentacosin-5(4H)-ona

                                             C40H59NO11

                                                            H3C
                                                                  O H
                                                             H
                                                                              H
                                             H2 N                                         H
                                                                      O           O               H        H
                                                    HO H H                        H           O
                                                                                       CH2                 O
                                                                          O                           H        H
                                                                                              H
                                                                                       H
                                                                                              O       O            H
                                                                          H           CH3              O
                                                                              O
                                                                                                               H
                                                                      H               H

                                                                      H2C



                                                                                                                                 53
Recommended INN: List 59                                     WHO Drug Information, Vol. 22, No. 1, 2008




 faxeladolum
 faxeladol                  3-[(1R,2R)-2-(dimethylaminomethyl)cyclohexyl]phenol

 faxéladol                  3-{(1R,2R)-2-[(diméthylamino)méthyl]cyclohexyl}phenol

 faxeladol                  3-[(1R,2R)-2-(dimetilaminometil)ciclohexil]fenol

                            C15H23NO

                                               CH3
                                               N
                                                   CH3
                                       H
                                   H




                              OH



 ferricum carboxymaltosum
 ferric carboxymaltose      poly[D-glucopyranosyl(1→4)]-D-gluconic acid complex of hydrated
                            iron(III) oxide

 carboxymaltose ferrique    complexe d'oxide de fer(III) et d'acide poly[D-glucopyranosyl(1→4)]-
                            D-gluconique hydraté

 carboximaltosa férrica     ácido poli[D-glucopiranosil(1→4)]-D-glucónico complejo de óxido de
                            hierro(III) hidratado

                            FeIIIw([C6H10O5]aC6H11O7)x(OH)yOz.nH2O




 flovagatranum
 flovagatran                (1R)-1-{N-[(benzyloxy)carbonyl]-D-phenylalanyl-L-prolinamido}=
                            butylboronic acid

 flovagatran                acide (1R)-1-({N-[(benzyloxy)carbonyl]-D-phénylalanyl-L-prolyl}=
                            amino)butylboronique

 flovagatrán                ácido (1R)-1-{N-[(benciloxi)carbonil]-D-fenilalanil-L-prolinamido}=
                            butilborónico

                            C27H36BN3O7

                                                                                           CH3
                                                                                       O
                                                         O            O   H
                                                     H            H
                                           O         N                            OH
                                                              N           N   B
                                                                          H
                                               O         H                    OH




54
WHO Drug Information, Vol. 22, No. 1, 2008                                                          Recommended INN: List 59


 gantenerumabum*
 gantenerumab                                immunoglobulin G1, anti-(human beta-amyloid peptides Aβ42 and
                                             Aβ40) human monoclonal antibody; gamma1 heavy chain (Homo
                                             sapiens VH-IGHG1) (229-215’)-disulfide with kappa light chain
                                             (Homo sapiens V-KAPPA-IGKC); (235-235”:238-238”)-bisdisulfide
                                             dimer

 ganténérumab                                immunoglobuline G1, anti-(peptides beta-amyloides Aβ42 et Aβ40
                                             humains) anticorps monoclonal humain; chaîne lourde gamma1
                                             (Homo sapiens VH-IGHG1) (229-215’)-disulfure avec la chaîne
                                             légère kappa (Homo sapiens V-KAPPA-IGKC); dimère (235-
                                             235”:238-238”)-bisdisulfure

 gantenerumab                                inmunoglobulina G1, anticuerpo monoclonal humano anti-(péptidos
                                             beta-amiloides Aβ42 et Aβ40 humanos); cadena pesada gamma1
                                             (Homo sapiens VH-IGHG1) (229-215’)-disulfuro con la cadena ligera
                                             kappa (Homo sapiens V-KAPPA-IGKC); dimero (235-235”:238-
                                             238”)-bisdisulfuro


                                             γ1- heavy chain / Chaîne lourde γ1 / Cadena pesada γ1

                                             QVELVESGGG       LVQPGGSLRL       SCAASGFTFS     SYAMSWVRQA      PGKGLEWVSA       50
                                             INASGTRTYY       ADSVKGRFTI       SRDNSKNTLY     LQMNSLRAED      TAVYYCARGK       100
                                             GNTHKPYGYV       RYFDVWGQGT       LVTVSSASTK     GPSVFPLAPS      SKSTSGGTAA       150
                                             LGCLVKDYFP       EPVTVSWNSG       ALTSGVHTFP     AVLQSSGLYS      LSSVVTVPSS       200
                                             SLGTQTYICN       VNHKPSNTKV       DKKVEPKSCD     KTHTCPPCPA      PELLGGPSVF       250
                                             LFPPKPKDTL       MISRTPEVTC       VVVDVSHEDP     EVKFNWYVDG      VEVHNAKTKP       300
                                             REEQYNSTYR       VVSVLTVLHQ       DWLNGKEYKC     KVSNKALPAP      IEKTISKAKG       350
                                             QPREPQVYTL       PPSRDELTKN       QVSLTCLVKG     FYPSDIAVEW      ESNGQPENNY       400
                                             KTTPPVLDSD       GSFFLYSKLT       VDKSRWQQGN     VFSCSVMHEA      LHNHYTQKSL       450
                                             SLSPGK                                                                            456

                                             κ-light chain / Chaîne légère κ / Cadena ligera κ

                                             DIVLTQSPAT       LSLSPGERAT       LSCRASQSVS     SSYLAWYQQK      PGQAPRLLIY        50
                                             GASSRATGVP       ARFSGSGSGT       DFTLTISSLE     PEDFATYYCL      QIYNMPITFG        100
                                             QGTKVEIKRT       VAAPSVFIFP       PSDEQLKSGT     ASVVCLLNNF      YPREAKVQWK        150
                                             VDNALQSGNS       QESVTEQDSK       DSTYSLSSTL     TLSKADYEKH      KVYACEVTHQ        200
                                             GLSSPVTKSF       NRGEC                                                             215

                                             The position of cysteine (C) residues that form disulphide bridges and asparagine residues
                                             that are N-glycosylated are in bold.




 golotimodum
 golotimod                                   D-γ-glutamyl-L-tryptophan

 golotimod                                   D-γ-glutamyl-L-tryptophane

 golotimod                                   D-γ-glutamil-L-triptófano

                                             C16H19N3O5

                                                   H    NH2
                                                                     H
                                                                     N        CO2H
                                             HO2C
                                                                 O         H



                                                                          N
                                                                          H




                                                                                                                                          55
Recommended INN: List 59                                         WHO Drug Information, Vol. 22, No. 1, 2008


 ibalizumabum*
 ibalizumab                    immunoglobulin G4, anti-(human CD4) humanized monoclonal
                               antibody Hu5A8 (TNX-355); gamma4 heavy chain [humanized VH
                               (Homo sapiens FR/Mus musculus CDR [8.8.15] from clone Mu5A8)-
                               Homo sapiens IGHG4*01] (136-219’)-disulfide with kappa light chain
                               [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR
                               [12.3.8] from clone Mu5A8)-Homo sapiens IGKC*01] ; (228-
                               228’:231-231”)-bisdisulfide dimer

 ibalizumab                    immunoglobuline G4, anti-(CD4 humain) anticorps monoclonal
                               humanisé Hu5A8 (TNX-355); chaîne lourde gamma4
                               [VH humanisé (Homo sapiens FR/Mus musculus CDR [8.8.15] du
                               clone 5A8)-Homo sapiens IGHG4] (136-219’)-disulfure avec la
                               chaîne légère kappa [V-KAPPA humanisé (Homo sapiens FR/Mus
                               musculus CDR [12.3.8] du clone Mu5A8)-Homo sapiens IGKC*01];
                               dimère (228-228”:231-231”)-bisdisulfure

 ibalizumab                    inmunoglobulina G4, anti-(CD4 humano) anticuerpo monoclonal
                               humanizado Hu5A8 (TNX-355); cadena pesada gamma4
                               [VH humanizado (Homo sapiens FR/Mus musculus CDR [8.8.15] del
                               clon 5A8)-Homo sapiens IGHG4] (136-219’)-disulfuro con la cadena
                               ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                               musculus CDR [12.3.8] del clon Mu5A8)-Homo sapiens IGKC*01];
                               dímero (228-228”:231-231”)-bisdisulfuro


                               Ig γ4-heavy chain / Chaîne lourde Ig γ4 / Cadena pesada Ig γ4

                               QVQLQQSGPE        VVKPGASVKM        SCKASGYTFT         SYVIHWVRQK   PGQGLDWIGY   50
                               INPYNDGTDY        DEKFKGKATL        TSDTSTSTAY         MELSSLRSED   TAVYYCAREK   100
                               DNYATGAWFA        YWGQGTLVTV        SSASTKGPSV         FPLAPCSRST   SESTAALGCL   150
                               VKDYFPEPVT        VSWNSGALTS        GVHTFPAVLQ         SSGLYSLSSV   VTVPSSSLGT   200
                               KTYTCNVDHK        PSNTKVDKRV        ESKYGPPCPS         CPAPEFLGGP   SVFLFPPKPK   250
                               DTLMISRTPE        VTCVVVDVSQ        EDPEVQFNWY         VDGVEVHNAK   TKPREEQFNS   300
                               TYRVVSVLTV        LHQDWLNGKE        YKCKVSNKGL         PSSIEKTISK   AKGQPREPQV   350
                               YTLPPSQEEM        TKNQVSLTCL        VKGFYPSDIA         VEWESNGQPE   NNYKTTPPVL   400
                               DSDGSFFLYS        RLTVDKSRWQ        EGNVFSCSVM         HEALHNHYTQ   KSLSLSLGK    449


                               Ig κ-light chain / Chaîne légère Ig κ / Cadena ligera Ig κ

                               DIVMTQSPDS        LAVSLGERVT        MNCKSSQSLL         YSTNQKNYLA   WYQQKPGQSP   50
                               KLLIYWASTR        ESGVPDRFSG        SGSGTDFTLT         ISSVQAEDVA   VYYCQQYYSY   100
                               RTFGGGTKLE        IKRTVAAPSV        FIFPPSDEQL         KSGTASVVCL   LNNFYPREAK   150
                               VQWKVDNALQ        SGNSQESVTE        QDSKDSTYSL         SSTLTLSKAD   YEKHKVYACE   200
                               VTHQGLSSPV        TKSFNRGEC                                                      219


 idrabiotaparinuxum natricum
 idrabiotaparinux sodium       nonasodium methyl (2-deoxy-3,4-di-O-methyl-2-{6-[5-(2-
                               oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido]=
                               hexanamido}-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-
                               β-D-glucopyranosyluronate)-(1→4)-(2,3,6-tri-O-sulfo-
                               α-D-glucopyranoside)-(1→4)-(2,3-di-O-methyl-
                               α-L-idopyranosyluronate)-(1→4)-2,3,6-tri-O-sulfo-
                               α-D-glucopyranoside

 idrabiotaparinux sodique      2-déoxy-3,4-di-O-méthyl-2-{[6-({5-[(3aS,4S,6aR)-2-oxohexahydro-
                               1H-thiéno[3,4-d]imidazol-4-yl]pentanoyl}amino)hexanoyl]amino}-
                               6-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3-di-O-méthyl-
                               β-D-glucopyranuronosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-
                               (1→4)-2,3-di-O-méthyl-α-L-idopyranuronosyl-(1→4)-2,3,6-tri-O-sulfo-
                               α-D-glucopyranoside de méthyle nonasodique




56
WHO Drug Information, Vol. 22, No. 1, 2008                                                               Recommended INN: List 59


 idrabiotaparinux sódico                     2-desoxy-3,4-di-O-metil-2-{[6-({5-[(3aS,4S,6aR)-2-oxohexahidro-
                                             1H-tieno[3,4-d]imidazol-4-il]pentanoil}amino)hexanoil]amino}-
                                             6-O-sulfo-α-D-glucopiranosil-(1→4)-2,3-di-O-metil-
                                             β-D-glucopiranuronosil-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopiranosil-
                                             (1→4)-2,3-di-O-metil-α-L-idopiranuronosil-(1→4)-2,3,6-tri-O-sulfo-
                                             α-D-glucopiranosido de metilo y nonasodico

                                             C53H79N4Na9O51S8

                                                                                                                                      O
                                                                                                                                          SO3Na

                                                                                                                 NaO3S                    O
                                                                                             O
                                                                                                 SO3Na                            O
                                                                                                                      O
                                                                        NaO3S                    O                        O                   O
                                                             O                                               CO2Na                                CH3
                                                                 SO3Na CO2Na             O                                                O
                                                                                                             OCH3                             SO3Na
                                                                 O                O O                O
                                                         OCH3                OCH3                O
                                                                                                     SO3Na            OCH3
                                             H3CO                    O
                                                                                                                  S
                                                             HN          O        OCH3
                                                                                                                              H
                                                                                                         H
                                                                                                             H            NH
                                                                                         N       O
                                                                                         H                       HN

                                                                                                                          O



 laropiprantum
 laropiprant                                 [(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-(methanesulfonyl)-
                                             1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid

 laropiprant                                 acide [(3R)-4-[(4-chlorophényl)méthyl]-7-fluoro-5-(méthanesulfonyl)-
                                             1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl]acétique

 laropiprant                                 ácido [(3R)-4-[(4-clorofenil)metil]-7-fluoro-5-(metanosulfonil)-
                                             1,2,3,4-tetrahidrociclopenta[b]indol-3-il]acético

                                             C21H19ClFNO4S

                                             F                                   CO2H


                                                                 N           H

                                                 O       S
                                                             CH3                    Cl
                                                     O



 levamlodipinum
 levamlodipine                               3-ethyl 5-methyl (4S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-
                                             6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

 lévamlodipine                               (4S)-2-[(2-aminoéthoxy)méthyl]-4-(2-chlorophényl)-6-méthyl-
                                             1,4-dihydropyridine-3,5-dicarboxylate de 3-éthyle et de 5-méthyle

 levamlodipino                               (4S)-2-[(2-aminoetoxi)metil]-4-(2-clorofenil)-6-metil-
                                             1,4-dihidropiridina-3,5-dicarboxilato de 3-etilo y 5-metilo




                                                                                                                                                        57
Recommended INN: List 59                                     WHO Drug Information, Vol. 22, No. 1, 2008


                           C20H25ClN2O5

                                            H
                                  H3C       N                         NH2
                                                         O
                                 O                       O      CH3
                           H3C
                                                H
                                     O              O
                                                    Cl




 lonaprisanum
 lonaprisan                11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-
                           17α-pregna-5,9-dien-3-one

 lonaprisan                11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-
                           17α-prégna-5,9-dién-3-one

 lonaprisán                11β-(4-acetilfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-
                           17α-pregna-5,9-dien-3-ona

                           C28H29F5O3

                                 O

                           H3C
                                                H        CH3 OH CF3

                                                                       F
                                                    H             F

                                                         H
                                 O



 metenkefalinum
 metenkefalin              L-tyrosylglycylglycyl-L-phenylalanyl-L-methionine
                           β-endorphin human-(1-5)-peptide

 métenkefaline             L-tyrosylglycylglycyl-L-phénylalanyl-L-méthionine
                           β-endorphine humaine-(1-5)-peptide

 metencefalina             L-tirosilglicilglicil-L-fenilalanil-L-metionina
                           β-endorfina humana-(1-5)-peptido

                           C27H35N5O7S

                           H L-Tyr    Gly   Gly     L -Phe     L-Met   OH




 milveterolum
 milveterol                N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[2-(4-{[(2R)-2-hydroxy-
                           2-phenylethyl]amino}phenyl)ethyl]amino}ethyl]phenyl}formamide

 milvétérol                N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[2-(4-{[(2R)-2-hydroxy-
                           2-phényléthyl]amino}phényl)éthyl]amino}éthyl]phényl}formamide

 milveterol                N-{2-hidroxi-5-[(1R)-1-hidroxi-2-{[2-(4-{[(2R)-2-hidroxi-
                           2-feniletil]amino}fenil)etil]amino}etil]fenil}formamida


58
WHO Drug Information, Vol. 22, No. 1, 2008                                                Recommended INN: List 59


                                             C25H29N3O4

                                                             H OH
                                                                    H
                                                                    N


                                             HO                                      N
                                                                                     H
                                                    HN         H                          H OH

                                                          O


 motesanibum
 motesanib                                   N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-{[(pyridin-
                                             4-yl)methyl]amino}pyridine-3-carboxamide

 motésanib                                   N-(3,3-diméthyl-2,3-dihydro-1H-indol-6-yl)-2-{[(pyridin-
                                             4-yl)méthyl]amino}pyridine-3-carboxamide

 motesanib                                   N-(3,3-dimetil-2,3-dihidro-1H-indol-6-il)-2-{[(piridin-
                                             4-il)metil]amino}piridina-3-carboxamida

                                             C22H23N5O

                                                                            HN
                                                                                   CH3
                                                              NH   O               CH3
                                             N
                                                         N              N
                                                                        H



 nepiderminum
 nepidermin                                  human epidermal growth factor, recombinant DNA origin

 népidermine                                 facteur humain de croissance épidermique, origine ADN
                                             recombinant

 nepidermina                                 factor de crecimiento epidérmico humano; origen: ADN
                                             recombinante

                                             C270H401N73O83S7

                                             H Asn Ser Asp Ser Glu Cys Pro Leu Ser His Asp Gly Tyr Cys
                                                                                             10

                                                 Leu His Asp Gly Val Cys Met Tyr Ile Glu Ala Leu Asp Lys
                                                                            20

                                                 Tyr Ala Cys Asn Cys Val Val Gly Tyr Ile Gly Glu             Arg Cys
                                                     30                                                40

                                                 Gln Tyr Arg Asp Leu Lys Trp Trp Glu Leu Arg            OH
                                                                                    50


 neratinibum
 neratinib                                   (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-
                                             7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

 nératinib                                   (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)méthoxy]phényl}amino)-3-cyano-
                                             7-éthoxyquinoléin-6-yl]-4-(diméthylamino)but-2-énamide

 neratinib                                   (2E)-N-[4-({3-cloro-4-[(piridin-2-yi)metoxi]fenil}amino)-3-ciano-
                                             7-etoxiquinolin-6-il]-4-(dimetilamino)but-2-enamida




                                                                                                                       59
Recommended INN: List 59                                   WHO Drug Information, Vol. 22, No. 1, 2008


                           C30H29ClN6O3

                                       H 3C        O          N


                                   CH3         HN                   CN
                                   N                         HN           Cl
                           H 3C                        O

                                                                          O
                                                                                N




 perampanelum
 perampanel                2-(6'-oxo-1'-phenyl-1',6'-dihydro[2,3'-bipyridin]-5'-yl)benzonitrile

 pérampanel                2-(6'-oxo-1'-phenyl-1',6'-dihydro[2,3'-bipyridin]-5'-yl)benzonitrile

 perampanel                2-(1'-fenil-6'-oxo-1',6'-dihidro[2,3'-bipiridin]-5'-il)benzonitrilo

                           C23H15N3O

                                           O

                                               N
                              CN


                                       N




 peretinoinum
 peretinoin                (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-
                           pentaenoic acid

 pérétinoïne               acide (2E,4E,6E,10E)-3,7,11,15-tétraméthylhexadéca-2,4,6,10,14-
                           penténoïque

 peretinoína               ácido (2E,4E,6E,10E)-3,7,11,15-tetrametilhexadeca-2,4,6,10,14-
                           pentaenoico

                           C20H30O2

                                   CH3             CH3        CH3         CH3
                                                                                CO 2H
                           H3C




 pexacerfontum
 pexacerfont               N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-
                           2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine

 pexacerfont               N-[(2R)-butan-2-yl]-8-(6-méthoxy-2-méthylpyridin-3-yl)-
                           2,7-diméthylpyrazolo[1,5-a][1,3,5]triazin-4-amine

 pexacerfont               N-[(2R)-butan-2-il]-8-(6-metoxi-2-metilpiridin-3-il)-
                           2,7-dimetilpirazolo[1,5-a][1,3,5]triazin-4-amina



60
WHO Drug Information, Vol. 22, No. 1, 2008                                                            Recommended INN: List 59


                                             C18H24N6O

                                                                                     CH3
                                             H3C             H           N
                                                             N
                                                                     N
                                                 H3C
                                                         H
                                                             N
                                                                     N
                                                                             H3C           N   OCH3
                                                             H3C


 pimavanserinum
 pimavanserin                                1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-
                                             3-{[4-(2-methylpropoxy)phenyl]methyl}urea

 pimavansérine                               1-[(4-fluorophényl)méthyl]-1-(1-méthylpipéridin-4-yl)-
                                             3-{[4-(2-méthylpropoxy)phényl]méthyl}urée

 pimavanserina                               1-[(4-fluorofenil)metil]-1-(1-metilpiperidin-4-il)-3-{[4-(2-metilpropoxi)=
                                             fenil]metil}urea

                                             C25H34FN3O2

                                                                 CH3
                                                                 N
                                                                                                      CH3
                                             F                                                  O
                                                                                                        CH3
                                                                             H
                                                                 N           N

                                                                     O


 piragliatinum
 piragliatin                                 (2R)-2-[3-chloro-4-(methanesulfonyl)phenyl]-
                                             3-[(1R)-3-oxocyclopentyl]-N-(pyrazin-2-yl)propanamide

 piragliatine                                (2R)-2-[3-chloro-4-(méthanesulfonyl)phényl]-
                                             3-[(1R)-3-oxocyclopentyl]-N-(pyrazin-2-yl)propanamide

 piragliatina                                (2R)-2-[3-cloro-4-(metanosulfonil)fenil]-3-[(1R)-3-oxociclopentil]-
                                             N-(pirazin-2-il)propanamida

                                             C19H20ClN3O4S

                                                 O O
                                                     S                                     N
                                             H3 C                        O

                                                    Cl                           N         N
                                                                                 H
                                                                         H
                                                                 H
                                                                                     O



 pomalidomidum
 pomalidomide                                4-amino-2-[(3RS)-2,6-dioxopiperidin-3-yl]-2H-isoindole-1,3-dione

 pomalidomide                                4-amino-2-[(3RS)-2,6-dioxopipéridin-3-yl]-2H-isoindole-1,3-dione

 pomalidomida                                4-amino-2-[(3RS)-2,6-dioxopiperidin-3-il]-2H-isoindol-1,3-diona




                                                                                                                            61
Recommended INN: List 59                                    WHO Drug Information, Vol. 22, No. 1, 2008


                           C13H11N3O4

                                      O                 O
                                                                and enantiomer
                                      N            NH           et énantiomère
                                          H                     y enantiómero
                                      O        O
                               NH2



 posaraprostum
 posaraprost               propan-2-yl (5Z)-7-{(1R,2S)-2-[(1E,3S)-3-hydroxy-5-phenylpent-
                           1-en-1-yl]-5-oxocyclopent-3-en-1-yl}hept-5-enoate

 posaraprost               (5Z)-7-{(1R,2S)-2-[(1E,3S)-3-hydroxy-5-phénylpent-1-én-1-yl]-
                           5-oxocyclopent-3-én-1-yl}hept-5-énoate de propan-2-yle

 posaraprost               (5Z)-7-{(1R,2S)-2-[(1E,3S)-3-hidroxi-5-fenilpent-1-en-1-il]-
                           5-oxociclopent-3-en-1-ilo}-hept-5-enoato de propan-2-ilo

                           C26H34O4

                           O    H
                                                                  O       CH3

                                                             O        CH3
                                H
                                          H OH




 pyronaridinum
 pyronaridine              4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-
                           2,6-bis[(pyrrolidin-1-yl)methyl]phenol

 pyronaridine              4-[(7-chloro-2-méthoxybenzo[b][1,5]naphthyridin-10-yl)amino]-
                           2,6-bis[(pyrrolidin-1-yl)méthyl]phénol

 pironaridina              4-[(7-cloro-2-metoxibenzo[b][1,5]naftiridin-10-il)amino]-
                           2,6-bis[(pirrolidin-1-il)metil]fenol

                           C29H32ClN5O2

                                              N                  Cl


                           H3CO       N
                                              HN
                                                                      N

                                                                 OH

                                                            N




62
WHO Drug Information, Vol. 22, No. 1, 2008                                                       Recommended INN: List 59


 rabeximod
 rabeximod                                   2-(9-chloro-2,3-dimethyl-6H-indolo[2,3-b]quinoxalin-6-yl)-
                                             N-[2-(dimethylamino)ethyl]acetamide

 rabeximod                                   2-(9-chloro-2,3-diméthyl-6H-indolo[2,3-b]quinoxalin-6-yl)-
                                             N-[2-(diméthylamino)éthyl]acétamide

 rabeximod                                   2-(9-cloro-2,3-dimetil-6H-indolo[2,3-b]quinoxalin-6-il)-
                                             N-[2-(dimetilamino)etil]acetamida

                                             C22H24ClN5O

                                                                              CH3
                                             Cl
                                                             N
                                                                                  CH3
                                                                 N
                                                         N
                                                                 H
                                                                 N                CH3
                                                                            N
                                                             O              CH3



 raltegravirum
 raltegravir                                 N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-[2-(5-methyl-
                                             1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-
                                             1,6-dihydropyrimidine-4-carboxamide

 raltégravir                                 N-[(4-fluorophényl)méthyl]-5-hydroxy-1-méthyl-2-[2-(5-méthyl-
                                             1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-
                                             1,6-dihydropyrimidine-4-carboxamide

 raltegravir                                 N-[(4-fluorofenil)metil]-5-hidroxi-1-metil-2-[2-(5-metil-1,3,4-oxadiazol-
                                             2-carboxamido)propan-2-il]-6-oxo-1,6-dihidropirimidina-
                                             4-carboxamida

                                             C20H21FN6O5

                                                             O H3 C     CH3             O
                                                     O                        N
                                             H3 C                N                           N
                                                                 H                           H
                                                     N N                N
                                                                 H3 C                   OH             F
                                                                              O



 regrelorum
 regrelor                                    N6-(N-ethylcarbamoyl)-2',3'-O-[(1S,2E)-3-phenylprop-2-ene-1,1-diyl]-
                                             5'-adenylic acid

 régrélor                                    acide N6-(N-éthylcarbamoyl)-2',3'-O-[(1S,2E)-3-phénylprop-2-ène-
                                             1,1-diyl]-5'-adénylique

 regrelor                                    ácido N6-(N-etilcarbamoil)-2',3'-O-[(1S,2E)-3-fenilprop-2-eno-
                                             1,1-diilo]-5'-adenílico




                                                                                                                       63
Recommended INN: List 59                                     WHO Drug Information, Vol. 22, No. 1, 2008


                           C22H25N6O8P

                                           O

                           H 3C        N       NH
                                       H
                                                        N
                                           N

                             O         O       N        N
                                  P
                                                O
                             HO OH


                                           O        O

                                                    H




 rolapitantum
 rolapitant                (5S,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-
                           8-phenyl-1,7-diazaspiro[4.5]decan-2-one

 rolapitant                (5S,8S)-8-({(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}méthyl)-
                           8-phényl-1,7-diazaspiro[4.5]décan-2-one

 rolapitant                (5S,8S)-8-({(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi}metil)-8-fenil-
                           1,7-diazaspiro[4.5]decan-2-ona

                           C25H26F6N2O2

                                  O


                                  HN                        CF3


                                           NH
                                                O
                                                                  CF3
                                                H CH3




 romiplostimum*
 romiplostim               L-methionyl[human   immunogloblin heavy constant gamma 1-
                           (227 C-terminal residues)-peptide (Fc fragment)] fusion protein with
                           41 amino acids peptide, (7-7':10,10')-bisdisulfide dimer

 romiplostim               (7-7':10,10')-bisdisulfure du dimère de la protéine de fusion entre le
                           L-méthionyl[chaine constante gamma 1 de l’immunoglobuline
                           humaine-(227 aminoacides C-terminaux)-peptide (fragment Fc)] et
                           un peptide de 41 aminoacides

 romiplostim               (7-7':10,10')-bisdisulfuro del dímero de la proteína de fusión entre la
                           L-metionil[cadena constante gamma 1 de la inmunoglobulina
                           humana-(227 aminoácidos C-terminales)-péptido (fragmento Fc)] y
                           un péptido de 41 aminoácidos




64
WHO Drug Information, Vol. 22, No. 1, 2008                                                             Recommended INN: List 59


                                             C2634H4086N722O790S18

                                             Monomer / Monomère / Monómero
                                             MDKTHTCPPC         PAPELLGGPS         VFLFPPKPKD        TLMISRTPEV        TCVVVDVSHE       50
                                             DPEVKFNWYV         DGVEVHNAKT         KPREEQYNST        YRVVSVLTVL        HQDWLNGKEY       100
                                             KCKVSNKALP         APIEKTISKA         KGQPREPQVY        TLPPSRDELT        KNQVSLTCLV       150
                                             KGFYPSDIAV         EWESNGQPEN         NYKTTPPVLD        SDGSFFLYSK        LTVDKSRWQQ       200
                                             GNVFSCSVMH         EALHNHYTQK         SLSLSPGKGG        GGGIEGPTLR        QWLAARAGGG       250
                                             GGGGGIEGPT         LRQWLAARA                                                               269

                                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                              7-7' 10-10' 42-102 42'-102' 148-206 148'-206'


 ronacaleretum
 ronacaleret                                 3-{3-[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-
                                             2-yl]amino}-2-hydroxypropoxy]-4,5-difluorophenyl}propanoic acid

 ronacaléret                                 acide 3-{3-[(2R)-3-{[1-(2,3-dihydro-1H-indèn-2-yl)-2-méthylpropan-
                                             2-yl]amino}-2-hydroxypropoxy]-4,5-difluorophényl}propanoïque

 ronacaleret                                 ácido3-{3-[(2R)-3-{[1-(2,3-dihidro-1H-inden-2-il)-2-metilpropan-
                                             2-il]amino}-2-hidroxipropoxi]-4,5-difluorofenil}propanoico

                                             C25H31F2NO4

                                                                                                F
                                                                                        F
                                                               H3C     CH3

                                                                        N               O                        CO2H
                                                                        H
                                                                                 H OH


 ropidoxuridinum
 ropidoxuridine                              1-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodopyrimidin-2(1H)-one

 ropidoxuridine                              1-(2-déoxy-β-D-érythro-pentofuranosyl)-5-iodopyrimidin-2(1H)-one

 ropidoxuridina                              1-(2-desoxi-β-D-eritro-pentofuranosil)-5-iodopirimidin-2(1H)-ona

                                             C9H11IN2O4

                                                                             I
                                                               N

                                             HO           O        N
                                                           O




                                                       OH


 rosonabantum
 rosonabant                                  (5RS)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-
                                             4,5-dihydro-1H-pyrazole-3-carboxamide

 rosonabant                                  (5RS)-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-N-(pipéridin-1-yl)-
                                             4,5-dihydro-1H-pyrazole-3-carboxamide

 rosonabant                                  (5RS)-5-(4-clorofenil)-1-(2,4-diclorofenil)-N-(piperidin-1-il)-
                                             4,5-dihidro-1H-pirazol-3-carboxamida




                                                                                                                                                65
Recommended INN: List 59                                         WHO Drug Information, Vol. 22, No. 1, 2008


                              C21H21Cl3N4O


                              Cl                             O
                                                       N              N
                                                  N               N
                                                                  H          and enantiomer
                                         Cl                                  et énantiomère
                                                       H                     y enantiómero



                                      Cl



 salirasibum
 salirasib                    2-{[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}benzoic
                              acid

 salirasib                    acide 2-{[(2E,6E)-3,7,11-triméthyldodéca-2,6,10-trién-1-yl]=
                              sulfanyl}benzoïque

 salirasib                    ácido 2-{[(2E,6E)-3,7,11-trimetildodeca-2,6,10-trien-1-il]=
                              sulfanil}benzoico

                              C22H30O2S

                                       CO 2H
                                                       CH3            CH3       CH3

                                       S                                           CH3




 sergliflozinum etabonas
 sergliflozin etabonate       2-[(4-methoxyphenyl)methyl]phenyl 6-O-(ethoxycarbonyl)-
                              β-D-glucopyranoside

 étabonate de sergliflozine   6-O-(éthoxycarbonyl)-β-D-glucopyranoside de 2-[(4-méthoxyphényl)=
                              méthyl]phényle

 etabonato de sergliflozina   6-O-(etoxicarbonil)-β-D-glucopiranósido de 2-[(4-metoxifenil)=
                              metil]fenilo

                              C23H28O9

                                                                 OCH3




                              H3C     O           O

                                              O              O O
                                                       OH
                                                  HO
                                                             OH




66
WHO Drug Information, Vol. 22, No. 1, 2008                                                 Recommended INN: List 59


 sitimagenum ceradenovecum*
 sitimagene ceradenovec                      (recombinant) replication restricted adenovirus (type 5) vector, E1
                                             and E3 deleted, containing/expressing the Herpes simplex virus
                                             thymidine kinase (HSV-tk) gene

 sitimagène céradénovec                      Vecteur adénovirus (type 5 recombinant défectif, délété de E1 et E3,
                                             contenant le gène thymidine kinase du virus de l’herpès simplex
                                             (Herpes simplex virus - HSV-tk)

 sitimagén ceradenovec                       Vector adenovirus (tipo 5 recombinante defectivo,con deleción de E1
                                             y E3, que contiene el gen timidina kinasa del virus del herpes
                                             simplex (Herpes simplex virus - HSV-tk)



 sotrastaurinum
 sotrastaurin                                3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-
                                             1H-pyrrole-2,5-dione

 sotrastaurine                               3-(1H-indol-3-yl)-4-[2-(4-méthylpipérazin-1-yl)quinazolin-4-yl]-
                                             1H-pyrrole-2,5-dione

 sotrastaurina                               3-(1H-indol-3-il)-4-[2-(4-metilpiperazin-1-il)quinazolin-4-il]-1H-pirrol-
                                             2,5-diona

                                             C25H22N6O2

                                                              H
                                                     O        N         O




                                                          N
                                                    N                  N
                                                                       H
                                                          N

                                                                  N
                                                                      CH3


 taranabantum
 taranabant                                  N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl}-
                                             2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide

 taranabant                                  N-[(2S,3S)-4-(4-chlorophényl)-3-(3-cyanophényl)butan-2-yl}-
                                             2-méthyl-2-{[5-(trifluorométhyl)pyridin-2-yl]oxy}propanamide

 taranabant                                  N-[(2S,3S)-4-(4-clorofenil)-3-(3-cianofenil)butan-2-il}-2-metil-
                                             2-{[5-(trifluorometil)piridin-2-il]oxi}propanamida

                                             C27H25ClF3N3O2

                                                          H3 C         H    O
                                                                                   O      CF3
                                             NC                         N
                                                                        H
                                                          H                 H3C   CH3 N




                                                     Cl




                                                                                                                         67
Recommended INN: List 59                                       WHO Drug Information, Vol. 22, No. 1, 2008


 tarenflurbilum
 tarenflurbil              (2R)-2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid

 tarenflurbil              acide (2R)-2-(2-fluoro-[1,1'-biphényl-4-yl])propanoïque

 tarenflurbilo             ácido (2R)-2-(2-fluoro-[1,1'-bifenil-4-il])propanoico

                           C15H13FO2

                                                 H    CH3
                                   F
                                                        CO2H




 teplizumabum*
 teplizumab                immunoglobulin G1, anti-[human CD3 epsilon (CD3E)] humanized
                           monoclonal antibody MGA031 [hOKT3gamma1(Ala-Ala)]; gamma1
                           heavy chain 236L>A, 337L>A [humanized VH (Homo sapiens
                           FR/Mus musculus CDR from clone OKT3)-Homo sapiens IGHG1*01,
                           117L>A (CH2 1.3), 118L>A (CH2 1.2)] (222-213’)-disulfide with
                           kappa light chain [humanized V-KAPPA (Homo sapiens FR/Mus
                           musculus CDR from clone OKT3)-Homo sapiens IGKC*01] ; (228-
                           228”: 231-231”)-bisdisulfide dimer

 téplizumab                immunoglobuline G1, anti-[CD3 epsilon humain (CD3E)] anticorps
                           monoclonal humanisé MGA031 [hOKT3gamma1(Ala-Ala)]; chaîne
                           lourde gamma1 [VH humanisé (Homo sapiens FR/Mus musculus
                           CDR du clone OKT3)-Homo sapiens IGHG1*01, 117L >A (CH2 1.3)
                           , 118L>A (CH2 1.2)] (222-213’)-disulfure avec la chaîne légère
                           kappa [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR
                           du clone OKT3)-Homo sapiens IGKC*01]; dimère (228-228”: 231-
                           231”)-bisdisulfure

 teplizumab                inmunoglobulina G1, anti-[CD3 epsilon humano (CD3E)] anticuerpo
                           monoclonal humanizado MGA031 [hOKT3gamma1(Ala-Ala)];
                           cadena pesada gamma1 [VH humanizada (Homo sapiens FR/Mus
                           musculus CDR del clon OKT3)-Homo sapiens IGHG1*01, 117L >A
                           (CH2 1.3) , 118L>A (CH2 1.2)] (222-213’)-disulfuro con la cadena
                           ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus
                           musculus CDR del clon OKT3)-Homo sapiens IGKC*01]; dímero
                           (228-228”: 231-231”)-bisdisulfuro

                           C6462H9938N1738O2022S46

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGGG VVQPGRSLRL SCKASGYTFT                       RYTMHWVRQA        PGKGLEWIGY         50
                           INPSRGYTNY NQKVKDRFTI SRDNSKNTAF                       LQMDSLRPED        TGVYFCARYY         100
                           DDHYCLDYWG QGTPVTVSSA STKGPSVFPL                       APSSKSTSGG        TAALGCLVKD         150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                       LYSLSSVVTV        PSSSLGTQTY         200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                       CPAPEAAGGP        SVFLFPPKPK         250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                       VDGVEVHNAK        TKPREEQYNS         300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                       PAPIEKTISK        AKGQPREPQV         350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                       VEWESNGQPE        NNYKTTPPVL         400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                       HEALHNHYTQ        KSLSLSPGK          449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCSASSSVS                       YMNWYQQTPG        KAPKRWIYDT         50'
                           SKLASGVPSR FSGSGSGTDY TFTISSLQPE                       DIATYYCQQW        SSNPFTFGQG         100'
                           TKLQITRTVA APSVFIFPPS DEQLKSGTAS                       VVCLLNNFYP        REAKVQWKVD         150'
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                       SKADYEKHKV        YACEVTHQGL         200'
                           SSPVTKSFNR GEC                                                                              213'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           22-96    22''-96''    23'-87'   23'''-87''' 133'-193' 133'''-193''' 146-202 146''-202''
                           213'-222 213'''-222'' 228-228'' 231-231''   263-323   263''-323''   369-427 369''-427''




68
WHO Drug Information, Vol. 22, No. 1, 2008                                                             Recommended INN: List 59


 terameprocolum
 terameprocol                                1,1'-[(2R,3S)-2,3-dimethylbutane-1,4-diyl]bis(3,4-dimethoxybenzene)

 térameprocol                                1,1'-[(2R,3S)-2,3-diméthylbutane-1,4-diyl]bis(3,4-diméthoxybenzène)

 terameprocol                                1,1'-[(2R,3S)-2,3-dimetilbutano-1,4-diil]bis(3,4-dimetoxibenceno)

                                             C22H30O4

                                                                                               OCH3
                                                                          H   CH3
                                             H3CO
                                                                                               OCH3
                                                                   H3C    H
                                             H3CO


 thrombinum alfa*
 thrombin alfa                               human thrombin (recombinant, glycoform α)

 thrombine alfa                              thrombine humaine (recombinante, glycoforme α)

 trombina alfa                               trombina humana (recombinante, glicoforma α)

                                             C1511H2342N418O436S15

                                             Light chain / Chaîne légère / Cadena ligera
                                             TFGSGEADCG LRPLFEKKSL EDKTERELLE                       SYIDGR                              36

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                                                                                          IVEG        SDAEIGMSPW       50
                                             QVMLFRKSPQ           ELLCGASLIS       DRWVLTAAHC       LLYPPWDKNF        TENDLLVRIG       100
                                             KHSRTRYERN           IEKISMLEKI       YIHPRYNWRE       NLDRDIALMK        LKKPVAFSDY       150
                                             IHPVCLPDRE           TAASLLQAGY       KGRVTGWGNL       KETWTANVGK        GQPSVLQVVN       200
                                             LPIVERPVCK           DSTRIRITDN       MFCAGYKPDE       GKRGDACEGD        SGGPFVMKSP       250
                                             FNNRWYQMGI           VSWGEGCDRD       GKYGFYTHVF       RLKKWIQKVI        DQFGE            295

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             9-155 64-80 209-223 237-267

                                             Glycosylation site / Site de glycosylation / Posición de glicosilación
                                             Asn-89


 totrombopagum
 totrombopag                                 (4Z)-2-(3,4-dimethylphenyl)-4-(2-{2-hydroxy-3'-(1H-tetrazol-5-yl)=
                                             [1,1'-biphenyl-3-yl]}hydrazinylidene)-5-methyl-2,4-dihydro-
                                             3H-pyrazol-3-one

 totrombopag                                 (4Z)-2-(3,4-diméthylphényl)-4-{2-[2-hydroxy-3'-(1H-tétrazol-5-yl)=
                                             [1,1'-biphényl-3-yl]]diazanylidène}-5-méthyl-2,4-dihydro-3H-pyrazol-
                                             3-one

 totrombopag                                 (4Z)-2-(3,4-dimetilfenil)-4-{2-[2-hidroxi-3'-(1H-tetrazol-5-il)=
                                             [1,1'-bifenil-3-il]]hidrazinilideno}-5-metil-2,4-dihidro-3H-pirazol-3-ona

                                             C25H22N8O2

                                                    H3C                                        HN N
                                                                                                         N
                                                                  N
                                                                      N                              N
                                                    N                 H
                                                        N                     OH
                                                                  O




                                                            CH3
                                             H3 C



                                                                                                                                             69
Recommended INN: List 59                              WHO Drug Information, Vol. 22, No. 1, 2008




 trabedersenum
 trabedersen               2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                           deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-
                           deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-
                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxyadenosine

 trabédersen               2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                           déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-
                           déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-
                           thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-déoxyadénosine

 trabedersén               2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-
                           P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                           tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                           P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-
                           (3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P-
                           tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-
                           P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxiadenosina

                           C177H225N60O94P17S17




 trelanserinum
 trelanserin               2-(7-fluoro-2-oxo-4-{2-[4-(thieno[3,2-c]pyridin-4-yl)piperazin-
                           1-yl]ethyl}-1,2-dihydroquinolin-1-yl)acetamide

 trélansérine              2-(7-fluoro-2-oxo-4-{2-[4-(thiéno[3,2-c]pyridin-4-yl)pipérazin-
                           1-yl]éthyl}-1,2-dihydroquinolein-1-yl)acétamide

 trelanserina              2-(7-fluoro-2-oxo-4-{2-[4-(tieno[3,2-c]piridin-4-il)piperazin-1-il]etil}-
                           1,2-dihidroquinolin-1-il)acetamida

                           C24H24FN5O2S

                                           O
                           H2N
                                       N
                                 O
                                                        N
                                                              N      N
                                 F



                                                                    S




70
WHO Drug Information, Vol. 22, No. 1, 2008                                                    Recommended INN: List 59


 tremelimumabum *
 tremelimumab                                immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human
                                             monoclonal CP-675206 clone 11.2.1 heavy chain), disulfide with
                                             human monoclonal CP-675206 clone 11.2.1 light chain, dimer

 trémélimumab                                immunoglobuline G2, anti-(protéine 4 cytotoxique du lymphocyte T
                                             humain (antigène CD 152)) dimère du disulfure entre la chaîne
                                             lourde et la chaîne légère de l’anticorps monoclonal humain clone
                                             11.2.1 du CP-675206

 tremelimumab                                inmunoglobulina G2, anti-(proteína 4 citotóxica de linfocitos T
                                             humanos (antígeno CD 152)) dímero del disulfuro entre la cadena
                                             pesada y la cadena ligera del anticuerpo monoclonal humano
                                             CP-675206 clon 11.2.1

                                             C6500H9974N1726O2026S52


 tridecactidum
 tridecactide                                alpha-1-13-corticotropin, human
                                             L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-
                                             L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine

 tridécactide                                alpha-1-13-corticotropine, humaine
                                             L-séryl-L-tyrosyl-L-séryl-L-méthionyl-L-glutamyl-L-histidyl-
                                             L-phénylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine

 tridecactida                                alfa-1-13-corticotropina, humana
                                             L-seril-L-tirosil-L-seril-L-metionil-L-glutamil-L-histidil-L-fenilalanil-
                                             L-arginil-L-triptofilglicil-L-lisil-L-prolil-L-valina

                                             C75H106N20O19S

                                             H Ser Tyr Ser       Met       Glu His Phe   Arg Trp Gly    Lys Pro Val OH
                                                                                                   10




 tropantiolum
 tropantiol                                  2-({[(1R,2R,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]=
                                             octan-2-yl]methyl}{2-[(2-sulfanylethyl)amino]ethyl}amino)ethanethiol

 tropantiol                                  2-({[(1R,2R,3S,5S)-3-(4-chlorophényl)-8-méthyl-8-azabicyclo[3.2.1]=
                                             octan-2-yl]méthyl}{2-[(2-sulfanyléthyl)amino]éthyl}amino)éthanethiol

 tropantiol                                  2-({[(1R,2R,3S,5S)-3-(4-clorofenil)- 8-azabiciclo[ 3.2.1]octan-
                                             2-il]metil}{2-[(2-sulfaniletil)amino]etil}amino)etanotiol

                                             C21H34ClN3S2

                                             Cl                   H


                                                                      N    CH3
                                                        H

                                                                H H
                                                            N                    SH
                                               HS                      N
                                                                       H




                                                                                                                         71
Recommended INN: List 59                                                  WHO Drug Information, Vol. 22, No. 1, 2008


 vatreptacogum alfa (activatum)*
 vatreptacog alfa (activated)      [158-aspartic acid, 296-valine, 298-glutamine]human coagulation
                                   factor VII activated, recombinant DNA origin

 vatreptacog alfa (activé)         [158-acide aspartique, 296-valine, 298-glutamine]facteur de
                                   coagulation VII humain activé, origine ADN recombinant

 vatreptacog alfa (activada)       [158-ácido aspártico, 296-valina, 298-glutamina]factor de
                                   coagulación VII humano activado ; origen ADN recombinante

                                   C1981H3051N561O620S27

                                   Light chain / Chaîne légère / Cadena ligera
                                   ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
                                   ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
                                   YCSDHTGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
                                   GR                                                     152
                                   Heavy chain / Chaîne lourde / Cadena pesada
                                     IVGGKDCP KGECPWQVLL LVNGAQLCGG                  TLINTIWVVS       AAHCFDKIKN       200
                                   WRNLIAVLGE HDLSEHDGDE QSRRVAQVII                  PSTYVPGTTN       HDIALLRLHQ       250
                                   PVVLTDHVVP LCLPERTFSE RTLAFVRFSL                  VSGWGQLLDR       GATALVLQVL       300
                                   NVPRLMTQDC LQQSRKVGDS PNITEYMFCA                  GYSDGSKDSC       KGDSGGPHAT       350
                                   HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV                  SQYIEWLQKL       MRSEPRPGVL       400
                                   LRAPFP                                                                              406
                                   Modified residues / Résidus modifiés / Residuos modificados                                       H NH2
                                                       E                         HO2C H NH2                      D     HO2C
                                   6-7-14-16-19-20-25-26-29-35                                                   63                       CO2H
                                               4-carboxyGlu                                                 3-hydroxyAsp
                                                                               HO2C              CO2H                                OH

                                   Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                   17-22       50-61       55-70        72-81       91-102 98-112
                                   114-127 135-262 159-164 178-194 310-329 340-368

                                   Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                   Ser-52 Ser-60 Asn-145 Asn-322




 velimogenum aliplasmidum*
 velimogene aliplasmid             plasmid DNA vector, expressing HLA-B7 and beta-2 microglobulin,
                                   driven by a Rous sarcoma virus promoter

 vélimogène aliplasmide            vecteur ADN plasmidique, contenant les gènes HLA-B7 et beta2-
                                   microglobuline, sous le contrôle du promoteur virus de sarcome de
                                   Rous

 velimogén aliplásmido             vector ADN de plásmído, que contiene los genes HLA-B7 y beta2-
                                   microglobulina, controlado por el promotor de virus del sarcoma de
                                   Rous




 voclosporinum
 voclosporin                       1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-
                                   N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl-
                                   2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]-
                                   N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]

 voclosporine                      1,11anhydro{L-alanyl-D-alanyl-N-méthyl-L-leucyl-N-méthyl-L-leucyl-
                                   N-méthyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-méthyl-
                                   2-(méthylamino)nona-6,8-diénoyl]-(2S)-2-aminobutanoyl-
                                   N-méthylglycyl-N-méthyl-L-leucyl-L-valyl-N-méthyl-L-leucyl]

 voclosporina                      1,11-anhidro[L-alanil-D-alanil-N-metil-L-leucil-N-metil-L-leucil-N-metil-
                                   L-valil-[(2S,3R,4R,6E)-3-hidroxi-4-metil-2-(metilamino)nona-
                                   6,8-dienoil][(2S)-2-aminobutanoil]-N-metilglicil-N-metil-L-leucil-L-valil-
                                   N-methyl-L-leucina]




72
WHO Drug Information, Vol. 22, No. 1, 2008                                                            Recommended INN: List 59


                                             C63H111N11O12

                                                                                                             CH2


                                                              CH3                     H3C
                                                                                CH3   H                    CH3
                                                                                                  OH
                                                      H3 C            H3C        H      H                   H
                                                              H                                   H                CH3
                                                      H3 C
                                                              N             N         N               N            N
                                                                                                      H
                                                                      O CH3       O CH3       O              O
                                             H3 C                 O                                                        O
                                                      H           CH3                                       H3C    N
                                                                                                                                 CH3
                                                H3C           N             O         O      H3 C O
                                                                      H           H                          H             H
                                                                      N           N           N              N                 CH3
                                                          O
                                                                                                                       O
                                                              H3C H         H CH3        H             H         CH3
                                                                                  H3 C                H3C
                                                                                             CH3




                                                                                                                                       73
Recommended INN: List 59                                                  WHO Drug Information, Vol. 22, No. 1, 2008




                            AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES


Recommended International Nonproprietary Names (Rec. INN): List 49
Dénominations communes internationales recommandées (DCI Rec.): Liste 49
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 49
(WHO Drug Information, Vol. 17, No. 2, 2003)

p. 123     suprimáse                insértese
           garenoxacina             garenoxacino



Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 248     certolizumabum pegolum
           certolizumab pegol       insert the following CAS
           certolizumab pégol       insérer le CAS suivant:
           certolizumab pegol       insértese el nombre del CAS por el siguiente:

                                    immunoglobulin, anti-(human tumor necrosis factor α) Fab' fragment (human
                                    mouse monoclonal CDP870 heavy chain, disulfide bonded with human mouse
                                    monoclonal CDP870 light chain), pegylated at Cys-227 on the heavy chain

                                    immunoglobuline, anti-(facteur α de nécrose tumorale humain) ; (disulfure entre
                                    le fragment Fab' de la chaîne lourde et la chaîne légère de l'anticorps monoclonal
                                    de souris CDP870 humanisé), pégylée à Cyst-227 sur la chaîne lourde

                                    inmunoglobulina, anti-(factor α de necrosis tumoral humano) fragmento Fab'
                                    (cadena pesada del anticuerpo monoclonal humanizado de ratón CDP870),
                                    disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón
                                    CDP870), pegilado Cis-227 de la cadena pesada



Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 61    beroctocogum alfa*
         beroctocog alfa            replace the chemical structure and molecular formula by the following ones
         béroctocog alfa            remplacer la structure chimique et la formule brute par les suivantes
         beroctocog alfa            sustitúyase la fórmula desarrollada y la fórmula molecular por las siguientes

                                    C3821H5813N1003O1139S35 + C3547H5400N956O1033S35




74
    WHO Drug Information, Vol. 22, No. 1, 2008                                                                     Recommended INN: List 59


                                             human blood-coagulation factor VIII-(1-740)-peptide

                                            ATRRYYLGAV         ELSWDYMQSD         LGELPVDARF          PPRVPKSFPF          NTSVVYKKTL           50
                                            FVEFTDHLFN         IAKPRPPWMG         LLGPTIQAEV          YDTVVITLKN          MASHPVSLHA           100
                                            VGVSYWKASE         GAEYDDQTSQ         REKEDDKVFP          GGSHTYVWQV          LKENGPMASD           150
                                            PLCLTYSYLS         HVDLVKDLNS         GLIGALLVCR          EGSLAKEKTQ          TLHKFILLFA           200
                                            VFDEGKSWHS         ETKNSLMQDR         DAASARAWPK          MHTVNGYVNR          SLPGLIGCHR           250
                                            KSVYWHVIGM         GTTPEVHSIF         LEGHTFLVRN          HRQASLEISP          ITFLTAQTLL           300
                                            MDLGQFLLFC         HISSHQHDGM         EAYVKVDSCP          EEPQLRMKNN          EEAEDYDDDL           350
                                            TDSEMDVVRF         DDDNSPSFIQ         IRSVAKKHPK          TWVHYIAAEE          EDWDYAPLVL           400
                                            APDDRSYKSQ         YLNNGPQRIG         RKYKKVRFMA          YTDETFKTRE          AIQHESGILG           450
                                            PLLYGEVGDT         LLIIFKNQAS         RPYNIYPHGI          TDVRPLYSRR          LPKGVKHLKD           500
                                            FPILPGEIFK         YKWTVTVEDG         PTKSDPRCLT          RYYSSFVNME          RDLASGLIGP           550
                                            LLICYKESVD         QRGNQIMSDK         RNVILFSVFD          ENRSWYLTEN          IQRFLPNPAG           600
                                            VQLEDPEFQA         SNIMHSINGY         VFDSLQLSVC          LHEVAYWYIL          SIGAQTDFLS           650
                                            VFFSGYTFKH         KMVYEDTLTL         FPFSGETVFM          SMENPGLWIL          GCHNSDFRNR           700
                                            GMTALLKVSS         CDKNTGDYYE         DSYEDISAYL          LSKNNAIEPR          S                    741


                                             human blood-coagulation factor VIII-(1649-2332)-peptide
                                                                                                                                  EI           1650
                                             TRTTLQSDQE         EIDYDDTISV         EMKKEDFDIY          DEDENQSPRS         FQKKTRHYFI           1700
                                             AAVERLWDYG         MSSSPHVLRN         RAQSGSVPQF          KKVVFQEFTD         GSFTQPLYRG           1750
                                             ELNEHLGLLG         PYIRAEVEDN         IMVTFRNQAS          RPYSFYSSLI         SYEEDQRQGA           1800
                                             EPRKNFVKPN         ETKTYFWKVQ         HHMAPTKDEF          DCKAWAYSSD         VDLEKDVHSG           1850
                                             LIGPLLVCHT         NTLNPAHGRQ         VTVQEFALFF          TIFDETKSWY         FTENMERNCR           1900
                                             APCNIQMEDP         TFKENYRFHA         INGYIMDTLP          GLVMAQDQRI         RWYLLSMGSN           1950
                                             ENIHSIHFSG         HVFTVRKKEE         YKMALYNLYP          GVFETVEMLP         SKAGIWRVEC           2000
                                             LIGEHLHAGM         STLFLVYSNK         CQTPLGMASG          HIRDFQITAS         GQYGQWAPKL           2050
                                             ARLHYSGSIN         AWSTKEPFSW         IKVDLLAPMI          IHGIKTQGAR         QKFSSLYISQ           2100
                                             FIIMYSLDGK         KWQTYRGNST         GTLMVFFGNV          DSSGIKHNIF         NPPIIARYIR           2150
                                             LHPTHYSIRS         TLRMELMGCD         LNSCSMPLGM          ESKAISDAQI         TASSYFTNMF           2200
                                             ATWSPSKARL         HLQGRSNAWR         PQVNNPKEWL          QVDFQKTMKV         TGVTTQGVKS           2250
                                             LLTSMYVKEF         LISSSQDGHQ         WTLFFQNGKV          KVFQGNQDSF         TPVVNSLDPP           2300
                                             LLTRYLRIHP         QSWVHQIALR         MEVLGCEAQD          LY                                      2332

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             153-179 528-554 1899-1903 2021-2169 2174-2326

                                             Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                             Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

                                             Modifications / Modifications / Modificaciones
                                             Y = 4-O-sulfotyrosyl


    * Electronic structure available on Mednet: http://mednet.who.int/
    * Structure électronique disponible sur Mednet: http://mednet.who.int/
    * Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                                                      75
Recommended INN: List 59   WHO Drug Information, Vol. 22, No. 1, 2008




76
